Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: Cohort study

BMJ (Online)

Volumn 341, Issue 7773, 2010, Pages 595-

  Kadri P, Sudarshan R ^a   Lao Sirieix, Ierre ^a   O'Donovan, Maria ^a,b   Debiram, Irene ^a   Das, Madhumita ^a   Blazeby, Jane M ^c   Emery, Jon ^d,e   Boussioutas, Alex ^f,g   Morris, Helen ^e   Walter, Fiona M ^d,e   Pharoah, Paul ^h   Hardwick, Richard H ^b   Fitzgerald, Rebecca C ^a  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANXIETY; ARTICLE; BARRETT ESOPHAGUS; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; ESOPHAGOSCOPY; FEMALE; GASTROSCOPY; HUMAN; IMMUNOCYTOCHEMISTRY; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

AGED; ANXIETY; BARRETT ESOPHAGUS; EQUIPMENT DESIGN; FEMALE; GASTROSCOPY; GELATIN SPONGE, ABSORBABLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; PATIENT SATISFACTION; PEPTIDES; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 77956846770     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4372     Document Type: Article

References (41)

1. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009;373:850-61.
2. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008;168:237-49.
3. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
4. Shaheen NJ, Sharma P, Overholt BF, Lightdale CJ, Wolfsen HC, Sampliner RE, et al. A randomized,multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett's esophagus (BE) containing dysplasia: interim results of the AIM Dysplasia Trial. Gastroenterology 2008;134:750-8.
5. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009;136:2101-14.
6. Pouw RE, Wirths K, Eisendrath P, Sondermeijer CM, Ten Kate FJ, Fockens P, et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2009;8:23-9.
7. Donaldson L. A pathological concern: understanding the rise in oesophageal cancer. Annual report of the Chief Medical Officer. 2007. www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/documents/ digitalasset/dh-086182.pdf.
8. Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ. Health-related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol 2009;7:613-23.
9. Kruijshaar ME, Kerkhof M, Siersema PD, Steyerberg EW, Homs MY, Essink-Bot ML. The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. Endoscopy 2006;38:873-8.
10. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
11. Lao-Sirieix P, Boussioutas A, Kadri SR, O'Donovan M, Debiram I, Das M, et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009;58:1451-9.
12. Corder AP, Jones RH, Sadler GH, Daniels P, Johnson CD. Heartburn, oesophagitis and Barrett'soesophagus inself-medicating patients in general practice. Br J Clin Pract 1996;50:245-8. (Pubitemid 126813831)
13. Jones R, Coyne K, Wiklund I. The Gastro-oesophageal Reflux Disease Impact Scale: a patient management tool for primary care. Aliment Pharmacol Ther 2007;25:1451-9. (Pubitemid 46848895)
14. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 1992;31:301-6.
15. Horowitz M, Wilner N, Alvarez W. Impact of event scale: ameasure of subjective stress. Psychosom Med 1979;41:209-18. (Pubitemid 9219271)
16. Likert R. A technique for the measurement of attitudes. Arch Psychol 1932;140:1-55.
17. Spielberger CD. Manual for the State-Trait Anxiety Inventory (form Y). Mind Garden, 1983.
18. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-9.
19. British Society of Gastroenterology. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. 2005. www.bsg.org.uk.
20. Amano Y, Ishimura N, Furuta K, Takahashi Y, Chinuki D, Mishima Y, et al. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc 2006;64:206-11.
21. Webb GP. Nutrition: a health promotion approach. 2nd ed. Arnold, 2002.
22. World Health Organization: BMI classification. 2010. http://apps.who.int/ bmi/index.jsp?introPage=intro-3.html.
23. Information Centre for Health and Social Care. Statistics on alcohol, England 2009. 2010. www.ic.nhs.uk/statistics-and-data-collections/health-and- lifestyles/alcohol/statistics-on-alcohol-england-2009-%5Bns%5D.
24. Information Centre for Health and Social Care. Statistics on smoking, England 2009. 2010. www.ic.nhs.uk/webfiles/publications/smoking09/Statistics-on- smoking-England-2009.pdf.
25. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005;129:1825-31.
26. Jobe BA, Hunter JG, Chang EY, Kim CY, Eisen GM, Robinson JD, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol 2006;101:2693-703.
27. Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. Ameta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol 2009;104:1533-9.
28. Ramirez FC, Akins R, Shaukat M. Screening of Barrett's esophagus with string-capsule endoscopy: a prospective blinded study of 100 consecutive patients using histology as the criterion standard. Gastrointest Endosc 2008;68:25-31.
29. Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008;57:1354-9.
30. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RKH, Vasudeva RS, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003;125:1670-7. (Pubitemid 37500431)
31. Sharma P. Barrett's esophagus. N Engl J Med 2009;361:2548-56.
32. Weller D, Coleman D, Robertson R, Butler P, Melia J, Campbell C, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. Br J Cancer 2007;97:1601-5. (Pubitemid 350249359)
33. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003;16:95-101.
34. Ferrini R, Mannino E, Ramsdell E, Hill L. Screening mammography for breast cancer: American College of Preventive Medicine practice policy statement. Am J Prev Med 1996;12:340-1. (Pubitemid 26376173)
35. Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl JMed 2009;360:2277-88.
36. UK National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2010. www.screening.nhs.uk/criteria.
37. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-84.
38. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010;10:87-101.
39. Barbiere JM, Lyratzopoulos G. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. Gastroenterology 2009;137:1869-76.
40. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
41. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 2009;69:4112-5.